J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers and as representatives of the underwriters, while Morgan Stanley is acting as book-running manager...J.P. Morgan Securities LLC and Morgan Stanley & Co
Addex Therapeutics SA, of Geneva, reported preclinical data showing that its mGlu5 negative allosteric modulator oral small molecule, dipraglurant, dose-dependently prevented the abnormal excitatory effect observed on brain slices of transgenic primary generalized torsion dystonia 1 (DYT1) mice overexpressing the human mutant TOR1A gene by decreasing the paradoxical neuronal activity induced by the dopamine D2 receptor agonist quinpirole. DYT1 is a common and severe genetic form of dystonia
BioWorld International | Wednesday, April 24, 2013
The company's financial advisors are Citigroup, Morgan Stanley and Ondra Partners, and its legal advisors are A&L Goodbody and Cadwalader, Wickersham and Taft LLP. (See BioWorld Today, Feb. 26, 2013, and April 16, 2013
Wedbush PacGrow (co-lead) Paradigm Capital $32 N/A Tesaro Inc. (Waltham, Mass.; TSRO)5 2/25/13 2/25/13 N/A N/A 30.78 Citigroup Morgan Stanley (co-lead) Leerink Swann Deutsche Bank Sec
Morgan Stanley acted as sole placement agent 1/7/13 Medicago Inc. (Quebec City) Loan N/A $15 Medicago gained a $15M loan from an undisclosed pharma company 1/18/13 Opexa Therapeutics Inc. (The Woodlands, Texas) Private offering of unsecured convertible promissory notes and warrants N/A $0.65 Opexa closed a private offering of notes and warrants for gross proceeds of $650,000 1/25/13 OPKO Health Inc. (Miami) Convertible senior notes offering N/A $175 OPKO Health priced its offering of $175M in 3
Morgan Stanley (1/1) +26% 12 Robert W. Baird (0/1) +26% 13 Leerink Swann (4/5) +25% 14 Stifel Nicolaus Weisel (1/2) +25% 15 Cowen & Co. (3/6) +20% 16 Rodman & Renshaw LLC (0/1) -12% 17 UBS Investment (1/1) -12% 18 Oppenheimer & Co. (0/2) -13% 19 Credit Suisse (1/1) -15% 20 RBC Capital Markets (0/1) -15% * The offerings in this chart include only those that were completed on U.S
Full Credit to Lead Underwriter, Ranked by After-Market Performance*# Rank Underwriter (IPOs as Lead/IPOs as Lead or Co-Manager) After-Market Performance (Average) 1 BMO Capital Markets (2/3) +93% 2 Goldman, Sachs & Co. (1/1) +89% 3 Lazard Capital Markets (1/3) +58% 4 Piper Jaffray (1/1) +43% 5 Bank of America Merrill Lynch (3/3) +33% 6 J.P. Morgan Securities (3/3) +28% 7 Citigroup Global Markets (including citibank) (3/3) +26% 8 Cowen & Co. (3/6) +26% 9 Morgan Stanley (1/1) +26% 10 Leerink
Morgan Stanley (1/1) $87.00 13 Robert W. Baird (0/1) $87.00 14 ThinkEquity LLC (0/1) $86.00 15 Goldman, Sachs & Co. (1/1) $81.00 16 Credit Suisse (1/1) $78.00 17 RBC Capital Markets (0/1) $78.00 18 Rodman & Renshaw LLC (0/1) $63.25 19 UBS Investment (1/1) $63.25 20 Piper Jaffray (1/1) $50.00 * The offerings in this chart include only those that were completed on U.S
J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers and as representatives of the underwriters, while Morgan Stanley is acting as book-running manager...J.P. Morgan Securities LLC and Morgan Stanley & Co